Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Here, we present an alternative protocol to actively induce experimental autoimmune encephalomyelitis in C57BL/6 mice, using the immunogenic epitope myelin oligodendrocyte glycoprotein (MOG)35-55 suspended in incomplete Freund's adjuvant containing the heat-killed Mycobacterium avium subspecies paratuberculosis.

Abstract

Experimental autoimmune encephalomyelitis (EAE) induced by myelin oligodendrocyte glycoprotein (MOG) requires immunization by a MOG peptide emulsified in complete Freund's adjuvant (CFA) containing inactivated Mycobacterium tuberculosis. The antigenic components of the mycobacterium activate dendritic cells to stimulate T-cells to produce cytokines that promote the Th1 response via toll-like receptors. Therefore, the amount and species of mycobacteria present during the antigenic challenge are directly related to the development of EAE. This methods paper presents an alternative protocol to induce EAE in C57BL/6 mice using a modified incomplete Freund's adjuvant containing the heat-killed Mycobacterium avium subspecies paratuberculosis strain K-10.

M. paratuberculosis, a member of the Mycobacterium avium complex, is the causative agent of Johne's disease in ruminants and has been identified as a risk factor for several human T-cell-mediated disorders, including multiple sclerosis. Overall, mice immunized with Mycobacterium paratuberculosis showed earlier onset and greater disease severity than mice immunized with CFA containing the strain of M. tuberculosis H37Ra at the same doses of 4 mg/mL. The antigenic determinants of Mycobacterium avium subspecies paratuberculosis (MAP) strain K-10 were able to induce a strong Th1 cellular response during the effector phase, characterized by significantly higher numbers of T-lymphocytes (CD4+ CD27+), dendritic cells (CD11c+ I-A/I-E+), and monocytes (CD11b+ CD115+) in the spleen compared to mice immunized with CFA. Furthermore, the proliferative T-cell response to the MOG peptide appeared to be highest in M. paratuberculosis-immunized mice. The use of an encephalitogen (e.g., MOG35-55) emulsified in an adjuvant containing M. paratuberculosis in the formulation may be an alternative and validated method to activate dendritic cells for priming myelin epitope-specific CD4+ T-cells during the induction phase of EAE.

Introduction

Experimental autoimmune encephalomyelitis (EAE) is a common model for the study of human demyelinating disorders1. There are several models of EAE: active immunization using different myelin peptides in combination with potent adjuvants, passive immunization by in vitro transfer of myelin-specific CD4+ lymphocytes, and transgenic models of spontaneous EAE2. Each of these models has specific features that allow different aspects of EAE to be studied, such as the onset, effector phase, or chronic phase. The myelin oligodendrocyte glycoprotein (MOG) model of EAE is a good model to study the immune-mediat....

Protocol

All mouse experiments were approved by the Institutional Animal Care and Use Committee of the Juntendo University School of Medicine (Approval Number 290238) and were conducted in accordance with the National Institutes of Health Guidelines for Animal Experimentation.

1. General comments on the experiment

  1. House the mice in individual cages in the animal facility under controlled, pathogen-free conditions at 23 °C ± 2 °C with 50% ± 10% humidity, .......

Representative Results

Groups of C57BL/6 mice (total n = 15/group) were immunized with MOG35-55 in an emulsion containing M. paratuberculosis or by the common method with CFA. All groups of mice manifested an acute monophasic disease characterized by a single peak of disability observed at 14-17 days, followed by a partial recovery of symptoms over the next 10 days (Figure 1A). Mice immunized with the adjuvant containing M. paratuberculosis, irrespectiv.......

Discussion

We demonstrated a robust alternative protocol to actively induce severe EAE in C57BL/6J mice using the peptide MOG35-55 emulsified in an adjuvant containing M. paratuberculosis10. The induction of EAE by this method resulted in a more severe disease than that induced by the common protocol with CFA. This difference could be due to the different lipidic components in the cell wall of the mycobacteria11. In fact, unlike other mycobacteria, M. paratuber.......

Acknowledgements

This work received support from a grant from the Japanese Society for the promotion of Science (grant no. JP 23K14675).

....

Materials

NameCompanyCatalog NumberComments
anti-mouse CD115 antibodyBiolegend, USA135505for cytofluorimetry 1:1,000
anti-mouse CD11b antibodyBiolegend, USA101215for cytofluorimetry 1:1,000
anti-mouse CD11c antibodyBiolegend, USA117313for cytofluorimetry 1:1,000
anti-mouse CD16/32  antibodyBiolegend, USA101302for cytofluorimetry 1:1,000
anti-mouse CD4  antibodyBiolegend, USA116004for cytofluorimetry 1:1,000
anti-mouse CD8a  antibodyBiolegend, USA100753for cytofluorimetry 1:1,000
anti-mouse I-A/I-E antibodyBiolegend, USA107635for cytofluorimetry 1:1,000
anti-mouse Ly-6C  antibodyBiolegend, USA128023for cytofluorimetry 1:1,000
BBL Middlebrook OADC EnrichmentThermo Fisher Scientific, USABD 211886for isolation and cultivation of mycobacteria
C57BL/6J miceCharles River Laboratory, Japan3 weeks old, male and female
FBS 10279-106Gibco Life Techologies, USA42F9155Kfor cell culture, warm at 37 °C before use
Freeze Dryer machineEyela, Tokyo, JapanFDU-1200for bacteria lyophilization
incomplete e Freund’s adjuvantDifco Laboratories, MD, USA263810for use in adjuvant
Middlebrook 7H9 BrothDifco Laboratories, MD, USA90003-876help in the growth of Mycobacteria
Mycobacterium avium subsp. paratuberculosis K-10ATCC, USABAA-968bacteria from bovine origin
Mycobacterium tuberculosis H37 Ra, DesiccatedBD Biosciences, USA743-26880-EAfor use in adjuvant
Mycobactin JAllied Laboratory, MO, USAgrowth promoter
Myelin Oligodendrocyte Glycolipid (MOG) 35-55AnaSpec, USAAS-60130-10encephalotigenic peptide
Ovalbumin (257-264)Sigma-Aldrich, USAS7951-1MGnegative control antigen  for proliferative assay
pertussis toxin solutionFujifilm Wako, Osaka Japan168-22471From gram-negative bacteria Bordetella pertussi, increases blood-brain barrier permeability
Polytron homogenizer PT 3100Kinematicafor mixing the antigen with the adjuvant
RPMI 1640 with L-glutamineGibco Life Techologies, USA11875093For cell culture
Thymidine, [Methyl-3H], in 2% ethanol, 1 mCiPerkinElmer, Waltham, MA, USANET027W001MCfor proliferation assay, use (1 μCi/well)
Zombie NIR Fixable Viability KitBiolegend, USA423105 cytofluorimetry, for cell viability

References

  1. Bittner, S., Afzali, A. M., Wiendl, H., Meuth, S. G. Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. Journal of Visualized Experiments. (86), e51275 (2014).
  2. Constantinescu, C. S., Farooqi, N., O'Brien, K., Gran, B.

Explore More Articles

Autoimmune EncephalomyelitisMycobacterium ParatuberculosisAdjuvant ActivityImmunogenicityAutoantigenMultiple SclerosisNeuroinflammationEAE ModelMycobacterium TuberculosisToll like ReceptorsJohne s Disease

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved